Who Paid My Doc
Mona Amin
Rheumatology Glendale, AZ Doctor of Osteopathy
NPI 1740476217 CMS profile 125054
5681 W Beverly Ln Ste 100, Glendale, AZ 85306
General payments
$445,769
Research payments
$98,540
Ownership & investment interest
$0
Research they led as principal investigator
$5,025,415
Through program year 2025, Mona Amin of Glendale, AZ is reported in the CMS Open Payments database as having received $445,769 across 1,771 general payments and $98,540 in research payments paid to them. Separately, studies naming them as principal investigator received $5,025,415 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $38,990 | 211 | |
| 2024 | General | $64,376 | 242 | |
| 2024 | Research | $5,705 | 2 | |
| 2023 | General | $114,011 | 274 | |
| 2023 | Research | $1,222 | 3 | |
| 2022 | General | $44,854 | 215 | |
| 2021 | General | $34,510 | 233 | |
| 2021 | Research | $1,585 | 2 | |
| 2020 | General | $35,037 | 211 | |
| 2020 | Research | $350 | 1 | |
| 2019 | General | $113,992 | 385 | |
| 2019 | Research | $89,679 | 1 |
Beside peers
- Mona Amin
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Mona Amin were reported at $38,990. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Mona Amin | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $113,992 | $744 | $153–$2,687 | $163 |
| 2020 | $35,037 | $462 | $98–$2,027 | $114 |
| 2021 | $34,510 | $531 | $101–$2,153 | $132 |
| 2022 | $44,854 | $627 | $125–$2,303 | $149 |
| 2023 | $114,011 | $741 | $145–$2,524 | $160 |
| 2024 | $64,376 | $830 | $166–$2,660 | $164 |
| 2025 | $38,990 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 42 drugsPart D claims
2,173
Drug cost
$2,124,256
Branded share of claims
36.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Humira(Cf) Pen Adalimumab | Brand | 80 | $665,086 | |
| Enbrel Sureclick Etanercept | Brand | 24 | $227,560 | |
| Rinvoq Upadacitinib | Brand | 25 | $183,682 | |
| Kevzara Sarilumab | Brand | 35 | $155,849 | |
| Cimzia (2 Pack) Certolizumab Pegol | Brand | 23 | $140,627 | |
| Humira(Cf) Adalimumab | Brand | 22 | $137,422 | |
| Orencia Abatacept | Brand | 21 | $129,158 | |
| Xeljanz Tofacitinib Citrate | Brand | 22 | $124,875 | |
| Otezla Apremilast | Brand | 16 | $79,143 | |
| Benlysta Belimumab | Brand | 18 | $78,361 |
The 10 drugs with the highest cost, of 42 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 138 billing codesPaid by Medicare
$4,895,173
Medicare patients
937
Services billed
278,643
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 74% | |
| Osteoporosis | 63% | |
| Chronic kidney disease | 31% | |
| Ischemic heart disease | 27% | |
| Depression | 25% | |
| Diabetes | 22% | |
| COPD | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, denosumab, 1 mg J0897 | Office | 320 | 29,941 | $615,171 |
| Injection, tocilizumab, 1 mg J3262 | Office | 21 | 108,320 | $510,101 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 | Office | 24 | 9,776 | $331,023 |
| Injection, golimumab, 1 mg, for intravenous use J1602 | Office | 48 | 34,302 | $307,456 |
| Injection, romosozumab-aqqg, 1 mg J3111 | Office | 28 | 26,670 | $208,247 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 15 | 3,810 | $95,019 |
| Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 | Office | 14 | 10,584 | $4,585 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 57 | 560 | $418 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 15 | 75 | $357 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 14 | 723 | $163 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 29 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| KRYSTEXXA |
|
$41,872 | — | — |
| KEVZARA |
|
$14,577 | 35 | — |
| RINVOQ |
|
$727 | 25 | — |
| XELJANZ |
|
$285 | 34 | — |
| SKYRIZI |
|
$280 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 29 with PatronRecords
1,780 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Rheumatology in Arizona
Related records
Rheumatology in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.